Los Angeles - 
(NewMediaWire) - November 1, 2021 - The Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of Revance
Therapeutics, Inc. (“Revance” or “the
Company”) (NASDAQ: RVNC) for violations of the
securities laws.
The investigation focuses on whether the Company
issued false and/or misleading statements and/or failed to disclose information
pertinent to investors. Revance is the subject of an FDA Form 483 posted on
October 12, 2021. The form details problems with the Company’s manufacturing
facility discovered during a July 2021 inspection. According to the FDA, a
working cell bank is noted as a cause of rejected GMP lots. The FDA also found
discrepancies between the Company’s proposal for licensure and the
manufacturing process in the facility. The agency notes that the Company’s
quality unit “lacks the responsibility and authority for the control, review,
and approval of outsourced activities….” Based on this news, shares of Revance
fell by 25% on the same day.
If you are a shareholder who
suffered a loss, click
here to participate.
We also encourage you to contact
Brian Schall of the Schall Law Firm, 2049
Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also
reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not
yet been certified, and until certification occurs, you are not represented by
an attorney. If you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.
310-301-3335
